Orion (ORNBV.HE) Stock Analysis & AI Equity Report
The ready report was written by the Valuatum engine on 7 July 2026 and holds the figures available then. A fresh report is written today, from today's data, and arrives by email — usually within about 30 minutes.
Orion (ORNBV.HE) overview
Orion (NASDAQ Helsinki: ORNBV.HE) stock analysis and AI equity research. Orion shares trade at 70.50 EUR; Valuatum rates ORNBV.HE BUY with a 74.80 EUR 12-month price target (+6.1% vs the current share price). This Drug Manufacturers - General equity research report covers Orion's valuation, segment-value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
52-week range 56.50 EUR – 75.30 EUR · 1-year change +13.4% · 3-year change +98.6%.
Executive summary
Orion Corporation (ORNBV.HE, NASDAQ Helsinki) is a Finnish pharmaceutical company whose growth profile is increasingly shaped by the rapid scale-up of Nubeqa royalties from its partnership with Bayer; in this Valuatum equity research report dated 7 July 2026 we rate the stock BUY with a 12-month target price of 74.80 EUR against a current price of 70.50 EUR, implying roughly 6.1% upside. Market capitalisation is EUR 9.9 bn and enterprise value is EUR 10 bn.
The core valuation tension is extreme concentration: approximately 83.6% of the EUR 10,030 million group enterprise value (EUR 8,385 million) is allocated to the Innovative Medicines segment and its Nubeqa royalty stream, even though the segment generates only about 34% of current group revenue. Adjusting reported 2024 segment EBIT of EUR 289 million for EUR 130 million of positive one-off milestones and EUR 41 million of pipeline write-downs leaves underlying recurring operating profit closer to EUR 200 million, so the allocation implies a demanding multiple of over 40x trailing recurring EBIT, while the legacy divisions supplying nearly two-thirds of revenue carry minimal valuation weight. On a reverse-valuation basis the embedded assumptions are already priced but achievable: Bayer's Nubeqa in-market sales of EUR 1.52 bn in 2024 must clear EUR 3.0 bn by 2027-2030 to justify the Innovative Medicines allocation, lifting group EBIT from EUR 417 million in 2024 to EUR 694 million by 2027. The base scenario implies EUR 70.46 per share (-0.1%), essentially the current price; the Bull scenario with label expansions lifts the value to EUR 84.45 (+19.8%), while a Nubeqa plateau near EUR 2 billion in the Bear case would compress the shares to EUR 45.35 (-35.7%).
Investment thesis — three reasons
Nubeqa's EUR 1.52bn 2024 sales must scale toward EUR 3.0bn by 2027 to sustain the EUR 8,385m Innovative Medicines EV allocation, which represents 83.6% of the EUR 10,030m group EV.
Segment value analysis — enterprise-value allocation
The segment value analysis decomposes Orion's enterprise value into the distinct businesses and options the market is paying for. The allocation across each segment is shown below; the full segment economics are in the report.
Scaling pool valued as a scalable, asset-light biotechnology royalty stream: under the Bayer partnership Orion receives a tiered royalty on global Nubeqa sales that begins at approximately 20% and escalates with volume, paired with captive tablet manufacturing. In 2024 Bayer reported global in-market Nubeqa sales of EUR 1.52 billion, from which Orion recognized EUR 368.3 million of recurring revenue (EUR 267.5 million in royalties, EUR 100.8 million in product sales), an effective blended monetization rate of approximately 24%. Adjusting reported 2024 EBIT of EUR 289 million for EUR 130 million in positive one-off milestones and EUR 41 million in pipeline write-downs leaves recurring EBIT near EUR 200 million, so the EUR 8,385 million allocation implies a demanding multiple of over 40x trailing recurring EBIT.
Reverse valuation
The reverse valuation tests whether the Nubeqa volume, margin and multiple assumptions embedded in Orion's EUR 10,030 million enterprise value are coherent, with the terminal volume of Nubeqa as the variable on which the scenarios almost entirely differ while the legacy manufacturing and branded divisions are held as a stable industrial base. Because Orion carries negligible net debt of EUR 116 million on 2025 forward estimates, the enterprise value bridges cleanly to a EUR 9,913 million equity market capitalisation, leaving equity holders directly exposed to operating performance.
Orion financial statements & estimates
All figures in EUR millions unless noted; per-share data in EUR.
Unlock the Orion ready report
The full PDF adds the complete reverse-valuation scenario model, segment financial statements and estimates, the full risk & catalyst analysis, and the institutional one-page snapshot. Instant download for €20.00. Written on 7 July 2026, from the figures available then.
Orion (ORNBV.HE) stock — frequently asked questions
Is Orion (ORNBV.HE) a buy or a sell?
Valuatum's latest AI equity report rates Orion (ORNBV.HE) BUY, with a 12-month price target of 74.80 EUR versus a 70.50 EUR share price (+6.1%). The full report explains the rationale behind the rating.
What is the Orion (ORNBV.HE) share price target?
The current Valuatum 12-month price target for Orion is 74.80 EUR, implying +6.1% versus the current share price. Unlock the report for the valuation behind the target.
How is Orion (ORNBV.HE) valued?
The Orion AI equity report values the company using segment-value analysis and a reverse valuation (a DCF-style framework), with segment financial estimates, key ratios, risks and catalysts. Buy the report to read the full valuation.
Where can I get the Orion (ORNBV.HE) equity research report?
Buy the Orion (ORNBV.HE) AI equity report PDF on this page for instant download, or generate a fresh report for any listed company.
Sources & methodology
- Primary data: Valuatum Equity Research, Orion report dated 7 July 2026 (company value map; group enterprise value EUR 10,030m, Innovative Medicines allocation EUR 8,385m, current quote 70.5 EUR).
- Consensus estimates: 2027E consensus EBIT of EUR 694m used in the target price formula; 2024-2027 consensus net sales growing from EUR 1.54 billion to EUR 2.19 billion.
- Market data: Ticker ORNBV.HE current price 70.50 EUR as of 7 July 2026; 2024 net sales EUR 1,542m; 2027E group EBITDA EUR 753m (analyst-generated estimate).
Valuatum reports are generated using Valuatum's AI equity research framework — a structured enterprise-value and segment value methodology built on 25+ years of professional equity research practice. See the methodology for the full approach.
Disclaimer: This is AI-generated research material for informational purposes only. It may include analytical rating and target-price language, but it is general research, not investment advice to any individual reader. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Orion
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.